Category: Guest content

New FDA Commissioner: What this means for Cancer Testing and Treatment

By Joshua Mansour, M.D. The head of the National Cancer Institute, Dr. Norman “Ned” Sharpless, will be temporarily appointed as acting commissioner of the Food and Drug administration amid the news of Dr. Scott Gottlieb stepping down for personal reasons.  Dr. Sharpless oversees billions in grants for research and federal funding at his current position.  Time will tell if […]


A Call to Healthcare Professionals: Contrary to what you’ve been taught, use social media

By Joshua Mansour, M.D.  From the beginning of medical school, one of the first things “instructional videos” that we had to watch during orientation was about “social media” and what “not to do”.  There began this stigma and it was frowned upon to use social media if you were a healthcare provider.  There are the […]


Business Continuity and Resiliency Planning for Biomedical and Research Organizations

By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity planning and why it is important? Emergencies may be infrequent…
The post Business Continuity and Resiliency…


Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators

This is a guest post from Pepper Hamilton Partners John P. Isacson and N. Nicole Stakleff. John can be contacted at [email protected] and Nicole can be contacted at [email protected] The Federal Circuit recently…
The post Obviousness-Type D…


Clause 8 Podcast Interview with Co-Author of the Hatch-Waxman Act

Former Congressman Henry Waxman was recently interviewed for the Clause 8 podcast about how he worked together with Sen. Orrin Hatch to pass the Hatch-Waxman Act and its aftermath.  Congressman…
The post Clause 8 Podcast Interview with Co-Author of the…


Securing the Right Space for Your Biotech Start-up

This is a guest post by Steven Lee, Senior Scientist in the Life Sciences Group at Environmental Health & Engineering (EH&E) Once you have the idea and the funding for a biotech start-up, you may think the biggest challenges are behind you. However, without proper planning and considerations, the environment you choose for your laboratory facility […]


Indian pharmaceutical patent prosecution: The changing role of Section 3(d)

This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstract India, like many developing countries, only recently…
The post Indian pharmaceutical patent prosecutio…


Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study

This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…


Estimated costs of production and potential prices for the WHO Essential Medicines List

This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persi…


Do NOT follow this link or you will be banned from the site!